+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 49Years
MALE
ID06993155

Study of Three Doses of Leflutrozole Taken Weekly to Improve Semen Quality in Men Aged 18 to 49 Years

Led by ReproNovo Aps · Updated on 2026-02-27

200

Participants Needed

4

Research Sites

17 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the effects of the drug leflutrozole on semen quality in men aged 18 to 49 years with low testosterone levels. This phase 2 clinical trial aims to find out whether leflutrozole can improve semen quality and what side effects participants may experience compared to a placebo. The trial is sponsored by ReproNovo Aps and focuses on testicular function and hormone levels. Participants will be randomly assigned to receive one of three doses of leflutrozole 0.05 mg, 0.1 mg, or 0.3 mg or a placebo. The medication is taken orally once a week for 16 weeks. The study is double-blind, meaning neither the participants nor the researchers know who receives the drug or placebo. Checkups and tests occur every 4 weeks during the treatment period. Men in the trial will provide semen samples to measure sperm count, motility, and other quality markers. Blood tests will monitor hormone levels such as testosterone and estradiol, as well as safety markers including prostate-specific antigen and ECG readings. Questionnaires will assess changes in libido and energy. Researchers will track adverse events throughout the 16 weeks to evaluate safety and effectiveness.

CONDITIONS

Brief Title

A Clinical Trial Evaluating the Efficacy and Safety of Leflutrozole on Testicular Function

Research Team

P

Public Disclosure

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here